Back to News
Market Impact: 0.2
BioArctic collaborator Novartis terminates agreement
Source: PR Newswire
Healthcare & BiotechCompany Fundamentals
BioArctic said Novartis Pharma AG has decided to terminate the Option, Collaboration and License Agreement the companies entered into in August 2025. The article excerpt does not specify what potential development the agreement was intended to explore or provide financial terms or further details about the termination.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
BIOA.B-0.60
NVS-0.20
More News
- Deutsche Bank downgrades Novartis stock rating to sell on valuation
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash